« Back to Farmacia Journal 3/2026

LONG-TERM EFFICACY AND SAFETY OF FARICIMAB VERSUS ANTI-VEGF IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A META-ANALYSIS AND SYSTEMATIC REVIEW

KAYLA MARITZA PUTRI SALMA ¹, AURIELLE ANNALICIA SETIAWAN ¹, REVINA MAHARANI ¹, EVIRA RAHMA AYA SOFIA ¹, NADIA ARTHA DEWI ²

Download Full Article PDF

Age-related macular degeneration (AMD) is a leading global cause of irreversible vision loss in older adults, primarily affect- ing the macula. Neovascular Age-related Macular Degeneration (nAMD) is treated with anti-vascular endothelial growth factor (anti-VEGF) agents. Faricimab, a dual inhibitor of VEGF and angiopoietin-2, has been developed to improve durabil- ity and anatomical outcomes. This study evaluated the long-term efficacy and safety of faricimab compared with anti-VEGF monotherapy in nAMD. A systematic search of the past 10 years identified five eligible papers, including four randomised controlled trials and one observational study. Data were pooled using Review Manager 5.4, and study quality was assessed using the Joanna Briggs Institute tool. No significant differences were observed in best-corrected visual acuity (BCVA) at one and two years. However, faricimab demonstrated greater reductions in central subfield thickness (CST) (MD = −6.70; P < 0.001), choroidal neovascularisation area (CNV) (MD = −0.49; P < 0.001) and leakage area (MD = −0.88; P < 0.001). Adverse event rates were comparable. Faricimab shows non-inferior efficacy and safety with improved anatomical outcomes in nAMD.